Name
Purdue University Globle
NU576 NP II – Primary Care of Women’s Health
Prof. Name
Date
Folic acid supplementation before conception and during early pregnancy is one of the most effective ways to prevent neural tube defects such as anencephaly. In addition, safe reproductive healthcare requires healthcare providers to understand pregnancy medication risks, appropriately evaluate amenorrhea in sexually active patients, and provide evidence-based counseling on oral contraceptives and fertility. These principles support safer prescribing, early pregnancy detection, and informed family planning decisions.
Folic acid, also known as vitamin B9, is essential for healthy fetal growth and neural tube development. The neural tube forms during the first few weeks of pregnancy—often before pregnancy is recognized—making adequate folic acid intake before conception and during early pregnancy critically important.
Research consistently shows that sufficient folic acid supplementation significantly lowers the risk of neural tube defects (NTDs), including anencephaly and spina bifida. Anencephaly is a severe congenital condition in which major portions of the brain, skull, and scalp fail to develop, making prevention through proper supplementation a major public health priority.
Healthcare providers should encourage individuals who are planning pregnancy or who could become pregnant to take the recommended daily amount of folic acid as part of routine preventive care.
Early folic acid intake provides several important benefits:
Reduces the risk of neural tube defects, including anencephaly.
Supports normal fetal brain and spinal cord development.
Protects fetal development during the earliest weeks of pregnancy.
Promotes healthier pregnancy outcomes.
Medication safety during pregnancy is a critical aspect of prenatal care. Healthcare providers must carefully evaluate the benefits and potential fetal risks before prescribing medications to pregnant patients or individuals who may become pregnant.
Historically, the U.S. Food and Drug Administration (FDA) categorized medications into Pregnancy Categories A, B, C, D, and X. Although these categories have largely been replaced by the Pregnancy and Lactation Labeling Rule (PLLR), understanding the previous system remains useful because it is still referenced in educational materials and older clinical resources.
Category A
Well-controlled human studies demonstrated no fetal risk.
Category B
Animal studies did not demonstrate fetal harm, but adequate human studies were unavailable or limited.
Category C
Animal studies suggested possible fetal risk. Medications may be prescribed when potential maternal benefits outweigh possible fetal risks.
Category D
Evidence indicates fetal risk in humans. However, these medications may still be appropriate in specific clinical situations when maternal benefits outweigh the risks.
Category X
Research demonstrated fetal abnormalities, and the risks clearly outweighed any potential benefit. These medications should not be used during pregnancy.
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor commonly prescribed for hypertension, has well-established fetal risks, particularly during the second and third trimesters of pregnancy.
Exposure to ACE inhibitors may result in:
Fetal kidney injury
Oligohydramnios (reduced amniotic fluid)
Poor fetal growth
Skull abnormalities
Neonatal kidney failure
Fetal or neonatal death in severe cases
For these reasons, ACE inhibitors are generally avoided during pregnancy, and alternative antihypertensive medications with better-established safety profiles should be considered.
Amenorrhea refers to the absence of menstrual periods and requires a systematic clinical evaluation. In any sexually active patient of reproductive age, pregnancy should always be excluded first because it is the most common cause of secondary amenorrhea.
A comprehensive assessment helps identify pregnancy, hormonal disorders, structural abnormalities, or other underlying medical conditions.
The initial evaluation typically includes:
Pregnancy testing (first-line investigation)
Sexually transmitted infection (STI) testing when clinically indicated
Complete menstrual history
Medical and surgical history
Medication review
Reproductive and sexual history
Physical examination based on clinical findings
Correctly distinguishing between primary and secondary amenorrhea guides diagnostic evaluation and treatment.
Primary amenorrhea is defined as the absence of the first menstrual period by approximately 15 years of age or within three years after the onset of breast development.
Possible causes include:
Chromosomal abnormalities
Congenital reproductive tract anomalies
Endocrine disorders
Hypothalamic or pituitary dysfunction
Secondary amenorrhea occurs when menstruation stops for three months or longer in individuals with previously regular menstrual cycles.
Common causes include:
Pregnancy
Polycystic ovary syndrome (PCOS)
Thyroid disorders
Hyperprolactinemia
Significant weight changes
Excessive exercise
Chronic illness
Certain medications
Effective contraceptive counseling helps patients use oral contraceptives safely while understanding what to expect when starting or discontinuing therapy.
Patients should be informed that fertility often returns rapidly after stopping birth control pills, with many individuals ovulating during the first menstrual cycle following discontinuation.
Healthcare providers should educate patients to:
Take oral contraceptives exactly as prescribed.
Avoid missing doses to maintain contraceptive effectiveness.
Understand that missed pills increase the risk of unintended pregnancy.
Recognize that fertility can return quickly after stopping oral contraceptives.
Begin another contraceptive method immediately if pregnancy prevention remains the goal after discontinuing oral contraceptives.
Clear patient education promotes medication adherence, informed reproductive planning, and improved pregnancy outcomes.
Folic acid supplementation before conception provides the greatest protection against neural tube defects.
Pregnancy should always be ruled out first in sexually active patients presenting with amenorrhea.
Medication safety should be reviewed before prescribing to individuals who are pregnant or may become pregnant.
ACE inhibitors, including lisinopril, should generally be avoided during pregnancy because of significant fetal risks.
Fertility commonly returns soon after oral contraceptives are discontinued.
Folic acid supports normal neural tube formation during early fetal development. Adequate intake before conception and during early pregnancy significantly reduces the risk of neural tube defects such as anencephaly.
Pregnancy is the most common cause of secondary amenorrhea in sexually active individuals. Confirming or excluding pregnancy helps guide further diagnostic evaluation.
Lisinopril and other ACE inhibitors can cause serious fetal complications, including kidney injury, oligohydramnios, impaired fetal growth, and neonatal renal failure, particularly during later pregnancy.
Yes. Ovulation may resume within the first menstrual cycle after discontinuing oral contraceptives, allowing pregnancy to occur soon after stopping the medication.
No. The FDA replaced the A, B, C, D, and X pregnancy categories with the Pregnancy and Lactation Labeling Rule (PLLR), which provides more detailed information about medication risks and benefits during pregnancy and breastfeeding.
American College of Obstetricians and Gynecologists. (2024). Amenorrhea: Absence of periods. https://www.acog.org/womens-health
Centers for Disease Control and Prevention. (2024). About folic acid. https://www.cdc.gov/folic-acid/about/index.html
U.S. Food and Drug Administration. (2015). Content and format of labeling for human prescription drug and biological products: Requirements for pregnancy and lactation labeling. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-labeling-human-prescription-drug-and-biological-products-requirements-pregnancy
World Health Organization. (2023). Family planning/contraception methods. https://www.who.int/news-room/fact-sheets/detail/family-planning-contraception
